Nanomedical Diagnostics, a Serra Capital II portfolio company, is set to present field effect biosensing for fragment-based drug discovery at the 2017 Society for Laboratory Automation and Screening (SLAS) conference in Washington, D.C. from Feb. 6 to Feb. 8.
Nanomed has developed a breakthrough electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and affinity data.
“Because Field Effect Biosensing measures electrical changes instead of mass, the technology can sense in solutions such as DMSO which cause a high level of background noise on optical sensors. We have detected in 10% DMSO with no effect,” says Nanomedical Diagnostics CEO, Ross Bundy. “This provides an excellent alternate methodology for researchers who struggle to measure in complex solvents that are necessary for their candidate compounds.”